179 related articles for article (PubMed ID: 34350670)
1. Scutellarein induces apoptosis and inhibits proliferation, migration, and invasion in ovarian cancer via inhibition of EZH2/FOXO1 signaling.
Lang X; Chen Z; Yang X; Yan Q; Xu M; Liu W; He Q; Zhang Y; Cheng W; Zhao W
J Biochem Mol Toxicol; 2021 Oct; 35(10):e22870. PubMed ID: 34350670
[TBL] [Abstract][Full Text] [Related]
2. Propofol inhibits proliferation and cisplatin resistance in ovarian cancer cells through regulating the microRNA‑374a/forkhead box O1 signaling axis.
Sun Y; Peng YB; Ye LL; Ma LX; Zou MY; Cheng ZG
Mol Med Rep; 2020 Mar; 21(3):1471-1480. PubMed ID: 32016462
[TBL] [Abstract][Full Text] [Related]
3. Scutellarein inhibits cancer cell metastasis in vitro and attenuates the development of fibrosarcoma in vivo.
Shi X; Chen G; Liu X; Qiu Y; Yang S; Zhang Y; Fang X; Zhang C; Liu X
Int J Mol Med; 2015 Jan; 35(1):31-8. PubMed ID: 25394920
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological inhibition of EZH2 using a covalent inhibitor suppresses human ovarian cancer cell migration and invasion.
Shi L; Zhang Q; Zhu S; Tang Q; Chen X; Lan R; Wang N; Zhu Y
Mol Cell Biochem; 2024 Apr; 479(4):831-841. PubMed ID: 37199893
[TBL] [Abstract][Full Text] [Related]
5. EZH2 promotes invasion and tumour glycolysis by regulating STAT3 and FoxO1 signalling in human OSCC cells.
Zheng M; Cao MX; Luo XJ; Li L; Wang K; Wang SS; Wang HF; Tang YJ; Tang YL; Liang XH
J Cell Mol Med; 2019 Oct; 23(10):6942-6954. PubMed ID: 31368152
[TBL] [Abstract][Full Text] [Related]
6. The anti-tumor effect of OP-B on ovarian cancer in vitro and in vivo, and its mechanism: An investigation using network pharmacology-based analysis.
Yuan S; Xu Y; Yi T; Wang H
J Ethnopharmacol; 2022 Jan; 283():114706. PubMed ID: 34614446
[TBL] [Abstract][Full Text] [Related]
7. EZH2 activates CHK1 signaling to promote ovarian cancer chemoresistance by maintaining the properties of cancer stem cells.
Wen Y; Hou Y; Yi X; Sun S; Guo J; He X; Li T; Cai J; Wang Z
Theranostics; 2021; 11(4):1795-1813. PubMed ID: 33408782
[No Abstract] [Full Text] [Related]
8. The long non-coding RNA DANCR regulates the inflammatory phenotype of breast cancer cells and promotes breast cancer progression via EZH2-dependent suppression of SOCS3 transcription.
Zhang KJ; Tan XL; Guo L
Mol Oncol; 2020 Feb; 14(2):309-328. PubMed ID: 31860165
[TBL] [Abstract][Full Text] [Related]
9. Goserelin promotes the apoptosis of epithelial ovarian cancer cells by upregulating forkhead box O1 through the PI3K/AKT signaling pathway.
Zhang N; Qiu J; Zheng T; Zhang X; Hua K; Zhang Y
Oncol Rep; 2018 Mar; 39(3):1034-1042. PubMed ID: 29286125
[TBL] [Abstract][Full Text] [Related]
10. Overcoming EZH2 Inhibitor Resistance by Taxane in PTEN-Mutated Cancer.
Ma L; Yan Y; Bai Y; Yang Y; Pan Y; Gang X; Karnes RJ; Zhang J; Lv Q; Wu Q; Huang H
Theranostics; 2019; 9(17):5020-5034. PubMed ID: 31410199
[No Abstract] [Full Text] [Related]
11.
Guo J; Zhu H; Li Q; Dong J; Xiong W; Yu K
Aging (Albany NY); 2021 Apr; 13(8):11665-11677. PubMed ID: 33879635
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of hsa_circ_0026123 suppresses ovarian cancer cell metastasis and proliferation through the miR‑124‑3p/EZH2 signaling pathway.
Yang X; Wang J; Li H; Sun Y; Tong X
Int J Mol Med; 2021 Feb; 47(2):668-676. PubMed ID: 33416105
[TBL] [Abstract][Full Text] [Related]
13. LncRNA LEF1-AS1 silencing diminishes EZH2 expression to delay hepatocellular carcinoma development by impairing CEBPB-interaction with CDCA7.
Gao J; Dai C; Yu X; Yin XB; Zhou F
Cell Cycle; 2020 Apr; 19(8):870-883. PubMed ID: 32178558
[TBL] [Abstract][Full Text] [Related]
14. LncRNA MEG3 inhibits the progression of prostate cancer by facilitating H3K27 trimethylation of EN2 through binding to EZH2.
Zhou Y; Yang H; Xia W; Cui L; Xu R; Lu H; Xue D; Tian Z; Ding T; Cao Y; Shi Q; He X
J Biochem; 2020 Mar; 167(3):295-301. PubMed ID: 31790140
[TBL] [Abstract][Full Text] [Related]
15. The Sp1/FOXC1/HOTTIP/LATS2/YAP/β-catenin cascade promotes malignant and metastatic progression of osteosarcoma.
Liu K; Ni JD; Li WZ; Pan BQ; Yang YT; Xia Q; Huang J
Mol Oncol; 2020 Oct; 14(10):2678-2695. PubMed ID: 32634265
[TBL] [Abstract][Full Text] [Related]
16. Effect of siRNA targeting EZH2 on cell viability and apoptosis of bladder cancer T24 cells.
Wang HF; Yang H; Hu LB; Lei YH; Qin Y; Li J; Bi CW; Wang JS; Huo Q
Genet Mol Res; 2014 Nov; 13(4):9939-50. PubMed ID: 25501205
[TBL] [Abstract][Full Text] [Related]
17. Long noncoding RNA ATB promotes ovarian cancer tumorigenesis by mediating histone H3 lysine 27 trimethylation through binding to EZH2.
Chen XJ; An N
J Cell Mol Med; 2021 Jan; 25(1):37-46. PubMed ID: 33336896
[TBL] [Abstract][Full Text] [Related]
18. Ropivacaine suppresses the progression of renal cell carcinoma through regulating the lncRNA RMRP/EZH2/CCDC65 axis.
Xiong Y; Zheng X; Deng H
Daru; 2024 Jun; 32(1):121-132. PubMed ID: 38008820
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of EZH2 via activation of SAPK/JNK and reduction of p65 and DNMT1 as a novel mechanism in inhibition of human lung cancer cells by polyphyllin I.
Li L; Wu J; Zheng F; Tang Q; Wu W; Hann SS
J Exp Clin Cancer Res; 2016 Jul; 35(1):112. PubMed ID: 27421653
[TBL] [Abstract][Full Text] [Related]
20. Curcumin inhibits the growth of triple-negative breast cancer cells by silencing EZH2 and restoring DLC1 expression.
Zhou X; Jiao D; Dou M; Zhang W; Lv L; Chen J; Li L; Wang L; Han X
J Cell Mol Med; 2020 Sep; 24(18):10648-10662. PubMed ID: 32725802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]